Wegovy Cost vs. Alternatives: Comparing Every GLP-1 Option in Class

How Wegovy Works: The GLP-1 Mechanism Behind the Price Tag

Semaglutide 2.4 mg mimics glucagon-like peptide-1, a gut hormone released after eating that signals satiety to the hypothalamus, slows gastric emptying, and augments glucose-dependent insulin secretion. Wegovy binds the GLP-1 receptor with a half-life of approximately 165 hours, which is what permits once-weekly dosing [1].

The drug's weight-loss effect is primarily central. GLP-1 receptors in the arcuate nucleus and other hypothalamic regions reduce appetite at the neurological level, not simply by delaying stomach emptying. Patients on semaglutide 2.4 mg report measurably lower hunger scores and reduced food cravings, which translates into sustained caloric deficits without the conscious willpower that behavioral-only programs demand [2].

This mechanism is shared across the GLP-1 receptor agonist class, but the drugs differ in receptor binding affinity, half-life, and whether they engage additional incretin pathways. Those pharmacologic differences explain both the efficacy gaps and the pricing variation among medications in this category.

Novo Nordisk received FDA approval for Wegovy in June 2021 specifically for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity [3]. The approval was based primarily on the STEP clinical trial program, which enrolled over 4,500 participants across four key studies.

Wegovy's Clinical Performance: What the STEP Trials Actually Showed

In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg lost 14.9% of their body weight at 68 weeks compared with 2.4% in the placebo group [1]. That 12.5 percentage-point difference remains one of the largest treatment effects documented for any single-agent anti-obesity medication in a Phase III trial.

STEP-2 studied semaglutide 2.4 mg in patients with type 2 diabetes and obesity. Weight loss was 9.6% at 68 weeks versus 3.4% with placebo, a predictably smaller effect because patients with type 2 diabetes typically lose less weight with GLP-1 agonists [4]. STEP-3 combined semaglutide with intensive behavioral therapy and reported 16.0% weight loss at 68 weeks, suggesting the drug and structured counseling have additive effects [5].

The completion rate in STEP-1 was 83.5%. Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) were the most common reason for discontinuation, affecting the semaglutide group at higher rates during dose escalation. Nausea occurred in 44.2% of semaglutide-treated participants versus 17.4% on placebo, though most cases were mild to moderate and transient [1].

"The magnitude of weight reduction seen with semaglutide 2.4 mg approaches what was previously achievable only with bariatric surgery," noted the STEP-1 investigators in their NEJM publication [1]. That comparison carries direct cost implications: bariatric surgery averages $20,000 to $35,000 upfront, while Wegovy's cumulative cost over 68 weeks of treatment exceeds $20,000 at list price.

Head-to-Head Cost and Efficacy: Wegovy vs. Every Alternative

The following breakdown covers each FDA-approved anti-obesity medication and positions it against Wegovy on both price and clinical evidence.

Wegovy vs. Zepbound (Tirzepatide)

Zepbound (tirzepatide 5 mg, 10 mg, or 15 mg) is the most direct competitor. A dual GIP/GLP-1 receptor agonist made by Eli Lilly, tirzepatide engages two incretin pathways rather than one. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo [6]. The 10 mg dose achieved 19.5%, and even the 5 mg dose yielded 15.0%, a result that matched Wegovy's STEP-1 outcome at the lowest tirzepatide dose.

Zepbound's list price runs approximately $1,060 per month, roughly $290 less than Wegovy's monthly cost at maintenance. Eli Lilly also launched a direct-to-consumer savings program offering vials at $399 per month for self-pay patients.

On raw numbers, Zepbound offers more weight loss at a lower list price. The catch: insurance coverage is inconsistent, and many commercial plans that cover Wegovy do not yet include Zepbound on their formularies. A patient whose plan covers Wegovy at a $25 copay would pay far less for Wegovy than for out-of-pocket Zepbound.

Wegovy vs. Saxenda (Liraglutide 3.0 mg)

Saxenda is the older GLP-1 option. It requires daily injections rather than weekly. In the SCALE Obesity trial (N=3,731), liraglutide 3.0 mg produced 8.0% mean weight loss at 56 weeks versus 2.6% with placebo [7]. That is roughly half the efficacy of semaglutide 2.4 mg.

Saxenda's list price ranges from $1,100 to $1,350 per month depending on pharmacy, making it nearly identical to Wegovy in cost. From a cost-per-pound-lost perspective, Saxenda is the worst value among injectable GLP-1s: similar price, half the weight loss, and daily injection burden. It remains on formulary at some plans that have not yet added Wegovy or Zepbound, which is the primary reason clinicians still prescribe it.

Wegovy vs. Contrave (Naltrexone-Bupropion ER)

Contrave is an oral combination pill, not a GLP-1 agonist. It works through the opioid and dopaminergic pathways. In the COR-I trial (N=1,742), naltrexone-bupropion produced 6.1% mean weight loss at 56 weeks versus 1.3% with placebo [8].

The monthly cost is approximately $99 to $300 depending on insurance and pharmacy. Contrave appeals to patients who refuse injections or cannot access GLP-1 drugs due to formulary restrictions. Its efficacy is less than half that of Wegovy, but it costs a fraction of the price for self-pay patients.

Wegovy vs. Qsymia (Phentermine-Topiramate ER)

Qsymia combines a sympathomimetic amine with an anticonvulsant. In the EQUIP trial (N=1,267), the top dose produced 10.9% mean weight loss at 56 weeks [9]. That places it between Saxenda and Wegovy in efficacy.

Monthly cost is approximately $150 to $250 with a manufacturer coupon. Qsymia is the second-most effective FDA-approved option by percentage weight loss after the injectable GLP-1/GIP drugs, and it is far cheaper. Drawbacks include cognitive side effects from topiramate ("brain fog," word-finding difficulty), teratogenicity requiring REMS certification, and cardiovascular concerns that prevented broad adoption.

Wegovy vs. Compounded Semaglutide

Compounded semaglutide from 503A and 503B pharmacies costs between $150 and $500 per month. These preparations exploded in availability during the FDA's semaglutide shortage designation. With the FDA ending the shortage in February 2024 and taking enforcement actions against compounders, the legal status of these products is precarious [10].

Compounded versions are not FDA-approved. They do not undergo the same manufacturing, stability, or sterility testing as branded Wegovy. Case reports of adverse events linked to compounded semaglutide (including bacterial contamination and incorrect dosing) have emerged. The cost savings are real but carry clinical and legal risk that patients and prescribers must weigh explicitly.

The Real Cost: What Patients Actually Pay

List price is a misleading number. Three factors determine what a patient actually spends on Wegovy each month.

Insurance coverage with prior authorization. Most commercial plans that cover Wegovy require documentation of BMI, failed lifestyle interventions, and sometimes failed trials of cheaper medications. A patient who clears prior authorization may pay a copay of $25 to $150 per month. Medicare Part D began covering Wegovy in 2024 following the SELECT trial cardiovascular indication, but coverage varies by plan.

Novo Nordisk savings programs. The manufacturer offers co-pay cards reducing out-of-pocket cost to as low as $0 for commercially insured patients. Uninsured patients can access a patient assistance program, though eligibility requires income documentation [3].

Self-pay and cash pricing. Without any insurance or coupon, Wegovy costs approximately $1,349 per month at GoodRx-reported retail prices. Over a year, that totals $16,188. Over the 68-week STEP-1 treatment period, cumulative cost approaches $22,900 at list price.

These numbers explain why access, not efficacy, is the primary barrier for most patients seeking GLP-1-based weight management.

Cost-Effectiveness: What the Health Economics Data Shows

A 2022 analysis published in JAMA Network Open modeled the cost-effectiveness of semaglutide 2.4 mg over a lifetime horizon. At list price, semaglutide exceeded conventional willingness-to-pay thresholds ($100,000 per quality-adjusted life year). At a net price reflecting rebates and discounts (estimated at 50 to 70% of list), semaglutide became cost-effective when accounting for downstream reductions in type 2 diabetes, cardiovascular events, and obstructive sleep apnea [11].

The SELECT trial, published in November 2023, demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg versus placebo in patients with established cardiovascular disease and obesity but without diabetes (N=17,604) [12]. That cardiovascular benefit changed the calculus: a drug that prevents heart attacks and strokes generates savings that offset its acquisition cost in high-risk populations.

Dr. Ildiko Lingvay, an endocrinologist at UT Southwestern, stated: "SELECT fundamentally shifted the conversation from cosmetic weight loss to cardiovascular risk reduction. Payors who refused coverage for obesity are now covering semaglutide for heart disease prevention" [12].

Insurance Formulary Positioning: Where Each Drug Sits

Formulary placement determines real-world cost more than list price. Here is the current pattern across major plan types.

Commercial employer plans tend to favor Wegovy due to its longer track record and the cardiovascular indication from SELECT. Zepbound is gaining formulary positions but remains excluded from roughly 40% of commercial plans as of early 2026. Saxenda is being dropped from formularies as Wegovy replaces it in the same therapeutic category.

Medicare Part D now covers Wegovy for patients with established cardiovascular disease following CMS guidance tied to the SELECT indication. Coverage for weight management alone (without cardiovascular disease) remains excluded under the Medicare anti-obesity drug exclusion statute, though legislation to change this is pending.

Medicaid coverage varies by state. As of 2026, fewer than half of state Medicaid programs cover any GLP-1 for obesity, creating significant disparities in access [13].

When an Alternative Makes More Clinical Sense Than Wegovy

Wegovy is not the optimal choice for every patient. Specific clinical scenarios favor alternatives.

Patients with type 2 diabetes and obesity may benefit more from tirzepatide, which produced superior A1C reduction alongside greater weight loss in the SURPASS program [14]. Using Zepbound (or its diabetes-indicated counterpart Mounjaro) addresses both conditions with a single medication.

Patients with binge eating disorder or alcohol use disorder may respond to naltrexone-bupropion (Contrave), which targets reward pathways relevant to those conditions. GLP-1 agonists reduce appetite but do not directly address compulsive eating behaviors mediated by the opioid system.

Patients who refuse injections have only oral options: Contrave, Qsymia, or the newly available oral semaglutide 50 mg (Rybelsus) for weight management, pending FDA approval of the higher-dose oral formulation [15]. The oral semaglutide weight-loss program (OASIS-1) showed 15.1% weight loss at 68 weeks with 50 mg daily oral dosing, matching injectable Wegovy's efficacy.

Patients on a strict budget with no insurance coverage may find Qsymia at $150 to $250 monthly the most practical option, given its 10.9% efficacy at a fraction of GLP-1 pricing.

What to Ask Your Prescriber Before Choosing

Three questions cut through the pricing confusion. First: "Is Wegovy on my formulary, and what is my expected copay after prior authorization?" The answer determines whether the list-price comparison even matters. Second: "Given my comorbidities, does clinical evidence favor one agent over another?" A patient with cardiovascular disease has a stronger evidence base for semaglutide; a patient with type 2 diabetes may get more value from tirzepatide. Third: "What is the plan if my insurance denies coverage?" Prescribers who handle GLP-1 prescriptions regularly have workflows for appeals, manufacturer assistance programs, and therapeutic substitutions.

The monthly cost a patient pays ranges from $0 (with commercial insurance and a co-pay card) to $1,349 (cash price without discount). That 100-fold range means the "cost" of Wegovy is not one number. It is a function of insurance, geography, formulary, and negotiation.